Hepatitis B Virus (HBV) antigen specific binding molecules, in particular T Cell Receptors (TCRs), TCR polypeptides and fragments thereof. The invention is also related to modified cells containing the TCRs, TCR polypeptides or fragments, pharmaceutical composition or kits including the same or methods of making or using the same as is described. In particular, the invention discloses TCRs or a fragments thereof, capable of binding to a peptide of a Hepatitis B Virus (HBV) Env polypeptide presented by an MHC class I molecule comprising an MHC class I σ-chain encoded by an HLA-Cw*08 allele.

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis B virus (HBV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the P and/or S open reading frames of HBV and are configured to provide substantially equivalent quantification of different genotypes and variants of HBV.

Single nucleotide polymorphisms (SNPs) that are indicative of relapse after a HBV direct-acting antiviral agent (DAA) treatment, such as a NUC treatment in a chronic hepatitis B (CHB) infected subject are described. Also described are methods of using the SNPs in predicting the relapse in the HBV DAA treatment of CHB infection.

Nucleic acid reagents and corresponding methods of using the same for monitoring and evaluating nucleic acid extraction and amplification reactions.

The present disclosure disclosed recombinase aided amplification (RAA) primers and kits for the detection of hepatitis c virus. Nucleotide sequences of the RAA primers include: an upstream primer: 5′-FITC-CTTGGGATATGATGATGAACTGGTCACCTAC-3′ (SEQ ID NO. 1); and a downstream primer: 5′-Biotin-AAGAGTAGCATCACAATCAGAACCTTAGCC-3′ (SEQ ID NO. 2). The HCV detection by using the RAA primers screened by the present disclosure has good specificity and high sensitivity (at least 10 copies/μL can be detected). The RAA primers can be used to prepare an HCV detection kit and construct an RAA amplification system. And combined with a lateral flow chromatography technology, the present disclosure can achieve rapid and low-cost detection of HCV and visual result judgment, no complex professional background is required, the use process is convenient and fast, and the detection results are safe and reliable.

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis C virus (HCV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the 5′ untranslated region of HCV and are configured to provide substantially equivalent quantification of different genotypes and variants of HCV.

A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.

A probe for detecting hepatitis B virus and a method for detecting an insertion site of hepatitis B virus at high efficiency based on the analysis method of next-generation sequencing using the probe is disclosed. A probe can be provided that is capable of confirming the insertion site of HBV in the human genome with a possibility of developing into liver cancer. In addition, by applying the probe to the analysis method of next-generation sequencing, HBV insertion sites in the human genome can be analyzed at low cost and high efficiency.

A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis C virus (HCV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the 5′ untranslated region of HCV and are configured to provide substantially equivalent quantification of different genotypes and variants of HCV.